Surotomycin

Drug Profile

Surotomycin

Alternative Names: CB-183,315; CB-315; CDAD therapy - Merck; MK-4261

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cubist Pharmaceuticals
  • Developer Merck & Co
  • Class Antibacterials; Lactones; Lipopeptides; Peptides
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium infections

Most Recent Events

  • 26 Feb 2016 Discontinued - Phase-III for Clostridium infections in USA, Canada, South Korea, Australia, United Kingdom, Sweden, Spain, Poland, Poland, Italy, Israel, Hungary, Germany, France, Czech Republic, Belgium, Austria and New Zealand (PO), because of unfavourable efficacy data and commercial opportunity (Merck & Co. 10-K, February 2016)
  • 04 May 2015 Phase-III clinical trials in Clostridium infections in Australia, South Korea and New Zealand (PO)
  • 01 May 2015 Cubist Pharmaceuticals completes a phase III trial in Clostridium-infections in USA, Canada, Israel and European Union (NCT01597505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top